Growth rate-corrected (GR) dose-response metrics across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 2 of 4: Calculated dose-response metrics. - Dataset (ID:20269)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Clinical Subtype | Transcriptional Subtype | Small Molecule | Antibody | Perturbagen Target | Perturbagen Class | Biological Replicate ID | Conc Unit | GR50 | GEC50 | GRmax | GRinf | GR Hill Coefficient | GR_AOC | GR r2 | Nominal Division Rate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| MDA-MB-134-VI | HR+ | Luminal | Cetuximab | EGFR | ErbB | 10077.026 | uM | inf | inf | 1.0500 | 1.0500 | 0.0000 | -0.0500 | -inf | 0.3999 | |
| SUM159PT | TNBC | Basal B | Cetuximab | EGFR | ErbB | 7918.018 | uM | inf | inf | 0.9278 | 0.9278 | 0.0000 | 0.0321 | 0.1456 | 3.0213 | |
| SUM1315MO2 | TNBC | Basal B | Cetuximab | EGFR | ErbB | 9797.006 | uM | inf | inf | 0.2291 | 0.2291 | 0.0000 | 0.2002 | 0.5018 | 0.4196 | |
| 184B5 | NM | Basal | Trastuzumab | HER2 | ErbB | 9095.026 | uM | inf | 6.71320 | 0.7144 | 0.5130 | 4.9565 | -0.0290 | 0.80 | 1.0168 | |
| HCC38 | TNBC | Basal B | Cetuximab | EGFR | ErbB | 9028.018 | uM | inf | inf | 0.8573 | 0.8573 | 0.0000 | 0.0500 | -0.0461 | 1.0242 | |
| SUM159PT | TNBC | Basal B | Cetuximab | EGFR | ErbB | 9042.018 | uM | inf | inf | 0.7732 | 0.7732 | 0.0000 | 0.1379 | 0.0911 | 3.2484 | |
| 184A1 | NM | Basal | Trastuzumab | HER2 | ErbB | 9047.026 | uM | inf | inf | 0.2837 | 0.2837 | 0.0000 | 0.2170 | 0.0804 | 0.5972 | |
| HCC1937 | TNBC | Basal A | Cetuximab | EGFR | ErbB | 7833.042 | uM | inf | inf | 0.8856 | 0.8856 | 0.0000 | 0.0972 | 0.0274 | 1.0332 | |
| HCC1937 | TNBC | Basal A | Cetuximab | EGFR | ErbB | 7834.018 | uM | inf | inf | 0.8939 | 0.8939 | 0.0000 | 0.0410 | 0.4149 | 1.8951 | |
| MDA-MB-134-VI | HR+ | Luminal | Trastuzumab | HER2 | ErbB | 10077.026 | uM | 7.0350 | 7.93710 | 0.4622 | -0.4084 | 4.9480 | -0.0133 | 0.9348 | 0.3999 | |
| HCC1395 | TNBC | Basal B | Cetuximab | EGFR | ErbB | 7816.042 | uM | inf | inf | 1.0005 | 1.0005 | 0.0000 | -0.0101 | -0.0006 | 0.9332 | |
| HCC1395 | TNBC | Basal B | Cetuximab | EGFR | ErbB | 9258.026 | uM | inf | inf | 0.7953 | 0.7953 | 0.0000 | 0.0354 | 0.3593 | 0.5632 | |
| HCC1395 | TNBC | Basal B | Cetuximab | EGFR | ErbB | 7813.018 | uM | 0.82620 | 0.82952 | 0.7195 | -0.0101 | 4.9982 | 0.0073 | 0.6447 | 0.8420 | |
| HCC1395 | TNBC | Basal B | Cetuximab | EGFR | ErbB | 9254.124 | uM | 1.07170 | 0.71327 | 0.7439 | 0.4322 | 4.9081 | -0.0186 | 0.7673 | 0.8067 | |
| HCC1395 | TNBC | Basal B | Cetuximab | EGFR | ErbB | 7814.042 | uM | 1.1580 | 1.97410 | 0.7528 | -0.7381 | 1.6997 | 0.0120 | 0.7787 | 0.8414 | |
| MDA-MB-453 | TNBC | Luminal | Trastuzumab | HER2 | ErbB | 9723.124 | uM | inf | 0.00115 | 0.4864 | 0.6553 | 4.9994 | 0.2269 | 0.8119 | 0.9827 | |
| MDA-MB-231 | TNBC | Basal B | Cetuximab | EGFR | ErbB | 7892.018 | uM | inf | 0.5010 | 0.8331 | 0.7197 | 1.2256 | 0.0122 | 0.8070 | 2.4903 | |
| BT-474 | HER2amp | Luminal | Trastuzumab | HER2 | ErbB | 9158.123 | uM | 0.01277 | 0.00885 | -0.0100 | 0.0993 | 0.6043 | 0.4533 | 0.9046 | 0.8769 | |
| BT-474 | HER2amp | Luminal | Trastuzumab | HER2 | ErbB | 9163.026 | uM | 0.00135 | 0.0020 | -0.6688 | -0.4240 | 1.5559 | 0.8993 | 0.9648 | 0.3738 | |
| MDA-MB-134-VI | HR+ | Luminal | Cetuximab | EGFR | ErbB | 7877.042 | uM | inf | inf | 0.9001 | 0.9001 | 0.0000 | 0.0283 | 0.1356 | 0.3414 | |
| HCC38 | TNBC | Basal B | Cetuximab | EGFR | ErbB | 9453.125 | uM | inf | inf | 0.9729 | 0.9729 | 0.0000 | 0.0022 | 0.4453 | 1.2351 | |
| HCC38 | TNBC | Basal B | Cetuximab | EGFR | ErbB | 7854.018 | uM | inf | inf | 0.7802 | 0.7802 | 0.0000 | 0.1098 | 0.010 | 1.2298 | |
| MDA-MB-134-VI | HR+ | Luminal | Cetuximab | EGFR | ErbB | 7876.042 | uM | inf | inf | 0.9178 | 0.9178 | 0.0000 | -0.0251 | 0.2224 | 1.0958 |